A Study of Tasisulam in Treating Participants With Malignant Melanoma
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the objective response rate (complete and
partial response) for participants who receive tasisulam after one prior systemic treatment
for unresectable or metastatic melanoma.